OneSource Specialty Pharma Ltd

Fri 4/09/2026,15:56:7 | NSE : ONESOURCE

₹1537.80-37.90 (-2.41%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1585.00

Previous Close

₹ 1575.70

Volume

112994

Mkt Cap ( ₹ Cr)

₹ 17634.40

High

₹ 1596.30

Low

₹ 1526.00

52 Week High

₹ 1925.00

52 Week Low

₹ 1057.00

Book Value Per Share

₹ 510.70

Dividend Yield

0.00

Face Value

₹ 1.00

What's Your Call?

Collective community sentiment on OneSource Specialty Pharma Ltd

Your Vote -

Buy

66.67%

Hold

0.00%

Sell

33.33%

66.67%

3 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

1537.80

55

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

55

Option Chain

Analyzes market sentiment, predicts OneSource Specialty Pharma Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • OneSource Specialty - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    3 Sep 2026, 12:47PM Intimation of the investor presentation

  • OneSource Specialty - Investor Presentation

    3 Sep 2026, 12:38PM Onesource Specialty Pharma Limited has informed the Exchange about Investor Presentation

  • OneSource Specialty - Copy of Newspaper Publication

    1 Sep 2026, 5:25PM Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication confirming dispatch of Notice of the 19th Annual Gene

  • OneSource Specialty - Updates

    31 Aug 2026, 10:36PM Onesource Specialty Pharma Limited has informed the Exchange regarding 'Intimation of Business Responsibility and Sustainability Report for FY 25-26'.

  • OneSource Specialty - Notice Of The 19Th AGM Dated September 23, 2026

    31 Aug 2026, 8:38PM Intimation of the Notice of the 19th AGM (2nd AGM after listing), to be held on September 23, 2026 at 5:00 pm through Video Conferencing or other Audi

  • OneSource Specialty - Business Responsibility and Sustainability Reporting (BRSR)

    31 Aug 2026, 8:35PM Business Responsibility and Sustainability Report for the FY 2026

  • OneSource Specialty - Reg. 34 (1) Annual Report.

    31 Aug 2026, 8:32PM Annual Report for FY 2025-26

  • OneSource Specialty - Shareholders meeting

    31 Aug 2026, 8:30PM Onesource Specialty Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 23, 2026

  • OneSource Specialty - Reg. 34 (1) Annual Report.

    31 Aug 2026, 8:30PM Annual Report for FY 2025-26

  • OneSource Specialty - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    31 Aug 2026, 7:05PM Intimation of Investors called scheduled on September 03, 2026 at 10:00 AM.

  • OneSource Specialty - Analysts/Institutional Investor Meet/Con. Call Updates

    31 Aug 2026, 6:52PM Onesource Specialty Pharma Limited has informed the Exchange about Schedule of meet

  • OneSource Specialty - Copy of Newspaper Publication

    29 Aug 2026, 7:42PM Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the 19th AGM of the Company

  • OneSource Specialty - Credit Rating

    18 Aug 2026, 1:17PM Onesource Specialty Pharma Limited has informed the Exchange about Credit Rating

  • OneSource Specialty - Announcement under Regulation 30 (LODR)-Credit Rating

    18 Aug 2026, 12:23PM Intimation of Credit Rating issued by India Ratings and Research Private Limited vide press release dated August 17, 2026

  • OneSource Specialty - Analysts/Institutional Investor Meet/Con. Call Updates

    31 Jul 2026, 12:56PM OneSource Specialty Pharma Limited has informed the Exchange about Earnings Call Transcript dated July 25, 2026

  • OneSource Specialty - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    31 Jul 2026, 12:44PM Intimation of Transcript of Earnings call dated July 25, 2026

  • OneSource Specialty - Change in Management

    27 Jul 2026, 7:05PM Onesource Specialty Pharma Limited has informed the Exchange about change in Management

  • OneSource Specialty - Announcement under Regulation 30 (LODR)-Change in Management

    27 Jul 2026, 6:57PM Changes in Senior Management Personnel (SMP) of the Company - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)

  • OneSource Specialty - Copy of Newspaper Publication

    26 Jul 2026, 11:10PM Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication

  • OneSource Specialty - Analysts/Institutional Investor Meet/Con. Call Updates

    25 Jul 2026, 3:02PM OneSource Specialty Pharma Limited has informed the Exchange about Link of Recording

  • OneSource Specialty - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    25 Jul 2026, 2:23PM Intimation of Audio Recording of Earnings call pertaining to the Unaudited Financial Results for the quarter ended June 30, 2026

  • OneSource Specialty - Updates

    24 Jul 2026, 10:39PM Onesource Specialty Pharma Limited has informed the Exchange regarding 'Allotment of ESOPs'.

  • OneSource Specialty - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    24 Jul 2026, 10:39PM Intimation of allotment of 2,900 ESOPs of Re.1 each under ONESOURCE ESOP 2021

  • OneSource Specialty - Press Release

    24 Jul 2026, 9:19PM Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated July 24, 2026, titled ""OneSource announces strong Q1FY27

  • OneSource Specialty - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    24 Jul 2026, 9:12PM OneSource announces strong Q1FY27 results Revenue up 37% YoY and EBITDA up 39% YoY

  • OneSource Specialty - Change in Management

    24 Jul 2026, 7:51PM Onesource Specialty Pharma Limited has informed the Exchange about change in Management of the Company

  • OneSource Specialty - Announcement under Regulation 30 (LODR)-Change in Management

    24 Jul 2026, 7:46PM Changes in the Senior Managament Personnel of the Company-Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Reg

  • OneSource Specialty - Outcome of Board Meeting

    24 Jul 2026, 7:04PM Onesource Specialty Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

  • OneSource Specialty - Board Meeting Outcome for Intimation Of The Outcome Of The Board Meeting Dated July 24, 2026, For The A

    24 Jul 2026, 6:59PM Outcome of the Board meeting dated July 24, 2026, for the approval of the unaudited financial results (Standalone and Consolidated) for the quarter en

  • OneSource Specialty has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    21 Jul 2026, 10:30PM As of June 2026, 30.48% is owned by Indian Promoters and 69.52% by Public. <p align=justify> Institutional holds 42.56% (Insurance Companies 2.86%) an

  • OneSource Specialty - Analysts/Institutional Investor Meet/Con. Call Updates

    21 Jul 2026, 12:32PM Onesource Specialty Pharma Limited has informed the Exchange about Schedule of meet on July 25, 2026

  • OneSource Specialty - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    21 Jul 2026, 12:21PM Intimation of Earnings Call to be held on July 25, 2026.

  • OneSource Specialty - Board Meeting Intimation for Approval Of The Unaudited Financial Results For The Quarter Ended June 30,

    20 Jul 2026, 6:23PM Onesource Specialty Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2026 ,inter alia, to co

  • OneSource Specialty - Updates

    14 Jul 2026, 10:03AM Onesource Specialty Pharma Limited has informed the Exchange regarding 'OneSource Specialty Pharma and Formycon AG announceStrategic Manufacturing Par

  • OneSource Specialty Pharma partners with Formycon AG for Biosimilar Manufacturing

    14 Jul 2026, 10:47AM OneSource Specialty Pharma Ltd. has entered into a strategic manufacturing partnership with Germany-based Formycon AG to support the production of bio

  • OneSource Specialty - Onesource Specialty Pharma And Formycon AG Announce\r\nStrategic Manufacturing Partnership For Biosimil

    14 Jul 2026, 10:01AM OneSource Specialty Pharma and Formycon AG announce Strategic Manufacturing Partnership for Biosimilars

  • OneSource Specialty - Updates

    9 Jul 2026, 10:50AM Onesource Specialty Pharma Limited has informed the Exchange regarding 'Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Req

  • OneSource Specialty - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 20

    9 Jul 2026, 10:41AM We refer to the intimation made earlier today by Dr. Reddy's Laboratories (DRL) regarding delay in commercial supplies of Semaglutide. \r\n\r\nRefer i

  • OneSource Specialty - General Updates

    8 Jul 2026, 6:43PM Onesource Specialty Pharma Limited has informed the Exchange about allotment of ESOPs

  • OneSource Specialty - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    8 Jul 2026, 6:36PM Allotment of 24,190 equity shares of Re. 1/- under ONESOURCE ESOP 2021 on July 08, 2026.

  • OneSource Specialty - Updates

    2 Jul 2026, 4:21PM Onesource Specialty Pharma Limited has informed the Exchange regarding 'Completion of US-FDA Inspection at Sterile Product Division facility at Bengal

  • OneSource Specialty - Completion Of US-FDA Inspection At Sterile Product Division (SPD) Facility At Bengaluru

    2 Jul 2026, 3:04PM We wish to inform that a routine current Good Manufacturing (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA)

  • OneSource Specialty - Trading Window

    24 Jun 2026, 6:23PM Onesource Specialty Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Re

  • OneSource Specialty - Disclosure under SEBI Takeover Regulations

    17 Jun 2026, 1:04PM Tenshi Pharmaceuticals Private Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board

  • OneSource Specialty Pharma Ltd

    28 Jul 2026 , 12:09PM OneSource Specialty Pharma Ltd delivered a strong Q1FY26 performance with consolidated revenue jumping 37.2% YoY to Rs.4,490.23 million. The company achieved a consolidated net profit of Rs.292.97 million, improving from a marginal position in Q1FY25. Standalone results were even stronger, with a net profit of Rs.512.25 million.

  • OneSource Specialty Pharma partners with German firm

    14 Jul 2026 , 12:06PM OneSource Specialty Pharma partners with German firm to manufacture biosimilars for global markets

  • OneSource collaborates with Xbrane Biopharma AB

    11 Jun 2025 , 10:05AM OneSource, Xbrane Biopharma announce Biosimilars Manufacturing Partnership for the global markets
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of OneSource Specialty Pharma Ltd stock 

Name March-26 March-25 March-24 March-23
Assets 7226.518 6691.688 957.877 1622.144
Liabilities 7226.518 6691.688 957.877 1622.144
Equity 11.462 11.443 4.01 4.01
Gross Profit 268.993 369.275 -88.239 -160.687
Net Profit 21.21 19.31 -391.165 -799.83
Cash From Operating Activities 55.175 -47.283 -107.211 -162.88
NPM(%) 1.5 1.48 -227.52 -2065.99
Revenue 1405.381 1299.589 171.919 38.714
Expenses 1136.388 930.314 260.158 199.401
ROE(%) 0.36 0.32 -6.67 -13.65

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to OneSource Specialty Pharma Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 860.25 -1.14 21.76 875.31 -26.19 0.58
Lotus Eye Hospital and Institute Ltd 109.43 0.14 1563.29 3189.53 0.39 0.00
Vaishali Pharma Ltd 8.32 -0.48 26.00 20008.97 15.42 0.00
Astec Lifesciences Ltd 554.45 -3.28 0.00 3417.41 -363.14 0.00

Company Info

Our Company was incorporated as a private limited company under the Companies Act, 1956, with the name and style of `Inbiopro Solutions Private Limited' and a certificate of incorporation dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore. The name of our Company was then changed to `Stelis Biopharma Private Limited', pursuant to a scheme of amalgamation and a certificate of incorporation pursuant to change of name dated December 24, 2014, was issued by the Registrar of Companies, Karnataka at Bangalore. Our Company was then converted from a private limited company to a public company on July 31, 2021, and consequently renamed as `Stelis Biopharma Limited' and a fresh certificate of incorporation dated July 31, 2021, was issued by the Registrar of Companies, Karnataka at Bangalore. Subsequently, the name of our Company was changed to its present name `Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore.Major Events and Milestones:2007- Our Company was incorporated under the name and style of `Inbiopro Solutions Private Limited'2014- The name of our Company was changed to `Stelis Biopharma Private Limited'2021- Our Company was converted from a private limited company to a public limited company and consequently renamed as `Stelis Biopharma Limited'2024- The name of our Company was changed to `Onesource Specialty Pharma Limited'- Demerger, transfer and vesting of the Demerged Undertaking from Strides and Steriscience into our Company on a going concern basis pursuant to the Scheme of Arrangement2025-OneSource Specialty Pharma Limited and Sweden-based biotechnology firm Xbrane Biopharma AB (listed on Nasdaq under the ticker XBRANE), have announced a strategic partnership for the commercial manufacturing of Xbrane&rsquo;s biosimilar portfolio for global markets.-OneSource Specialty Pharma Limited has received a "Voluntary Action Indicated" (VAI) classification from the U.S. Food and Drug Administration (USFDA), confirming its continued compliance.

Our Company was incorporated as a private limited company under the Companies Act, 1956, with the name and style of `Inbiopro Solutions Private Limited' and a certificate of incorporation dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore. The name of our Company was then changed to `Stelis Biopharma Private Limited', pursuant to a scheme of amalgamation and a certificate of incorporation pursuant to change of name dated December 24, 2014, was issued by the Registrar of Companies, Karnataka at Bangalore. Our Company was then converted from a private limited company to a public company on July 31, 2021, and consequently renamed as `Stelis Biopharma Limited' and a fresh certificate of incorporation dated July 31, 2021, was issued by the Registrar of Companies, Karnataka at Bangalore. Subsequently, the name of our Company was changed to its present name `Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore.Major Events and Milestones:2007- Our Company was incorporated under the name and style of `Inbiopro Solutions Private Limited'2014- The name of our Company was changed to `Stelis Biopharma Private Limited'2021- Our Company was converted from a private limited company to a public limited company and consequently renamed as `Stelis Biopharma Limited'2024- The name of our Company was changed to `Onesource Specialty Pharma Limited'- Demerger, transfer and vesting of the Demerged Undertaking from Strides and Steriscience into our Company on a going concern basis pursuant to the Scheme of Arrangement2025-OneSource Specialty Pharma Limited and Sweden-based biotechnology firm Xbrane Biopharma AB (listed on Nasdaq under the ticker XBRANE), have announced a strategic partnership for the commercial manufacturing of Xbrane&rsquo;s biosimilar portfolio for global markets.-OneSource Specialty Pharma Limited has received a "Voluntary Action Indicated" (VAI) classification from the U.S. Food and Drug Administration (USFDA), confirming its continued compliance.

Parent Organisation

OneSource Specialty Pharma Ltd.

Founded

12/06/2007

Managing Director

Mr.Neeraj Sharma

NSE Symbol

ONESOURCEEQ

FAQ